Resolving the microcosmos of complex samples: UPLC/travelling wave ion mobility separation high resolution mass spectrometry for the analysis of in vivo drug metabolism studies
Tóm tắt
In vivo drug metabolism studies with low concentrations of analytes and high matrix burden are challenging. Of special interest are ‘first-in-man’ studies in early stages of pharmaceutical development that do not use 14C labeled drug candidates. Beside conventional MS-fishing techniques which are biased towards known/expected metabolites and mass defect filtration procedures, this paper focuses on the untargeted/unbiased analysis of drug related compounds in complex matrices using two orthogonal separation techniques: UPLC and TWIMS. Standard sample material after oral administration of a drug compound to rats was investigated by UPLC/TWIMS in MSE acquisition mode using interlaced collision energies for the parallel detection of [M+H]+ parent ions and fragments. Due to the fragmentation after ion mobility separation in the transfer region of the Synapt G2-triwave device, [M+H]+ ion species are aligned with their related fragments by virtue of possessing the same retention time and drift time profile. Four dimensional data analysis of the continuum raw data was performed by automated peak picking and alignment within the MSE viewer software. As result, completely purified MS- and MS/MS-data of metabolites were extracted from raw mass data with high matrix burden and were used without compromise for structure elucidation. This analytical methodology is universally applicable for the unbiased/untargeted and robust analysis of any analyte of interest in complex matrices, including small molecules, peptides and proteins. The high quality data files can be used as data repositories for the purpose of retrospective analysis which is of particular interest for the long term process in drug development.
Tài liệu tham khảo
FDA, Food and Drug Administration, Center for Drug Evaluation and research (CDER), U,S. Department of Health and Human Services (2008) Safety testing of drug metabolites, Guidance for Industry, http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0065-GDL.pdf
ICH, International conference on harmonization of technical requirements for registration of pharmaceuticals for human use (2009) ICH harmonized tripartite guideline, Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2) http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf
Obach RS, Nedderman AN, Smith DA (2012) Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary? Xenobiotica 42:45–56
Clarke NJ, Rindgen D, Korfmacher WA, Cox KA (2001) Systematic LC/MS metabolite identification in drug discovery. Anal Chem 73:430A–439A
Li AC, Alton D, Bryant MS, Shou WZ (2005) Simultaneously quantifying parent drugs and screening for metabolites in plasma pharmacokinetic samples using selected reaction monitoring information-dependent acquisition on a QTrap instrument. Rapid Commun Mass Spectrom 19:1943–1950
Shou WZ, Magis L, Li AC, Naidong W, Bryant MS (2005) A novel approach to perform metabolite screening during the quantitative LC-MS/MS analyses of in vitro metabolic stability samples using a hybrid triple-quadrupole linear ion trap mass spectrometer. J Mass Spectrom 40:1347–1356
Li AC, Gohdes MA, Shou WZ (2007) 'N-in-one' strategy for metabolite identification using a liquid chromatography/hybrid triple quadrupole linear ion trap instrument using multiple dependent product ion scans triggered with full mass scan. Rapid Commun Mass Spectrom 21:1421–1430
Triolo A, Altamura M, Dimoulas T, Guidi A, Lecci A, Tramontana M (2005) In vivo metabolite detection and identification in drug discovery via LC-MS/MS with data-dependent scanning and postacquisition data mining. J Mass Spectrom 40:1572–1582
Peterman SM, Duczak N, Kalgutkar AS, Lame ME, Soglia JR (2006) Application of a linear ion trap/orbitrap mass spectrometer in metabolite characterization studies: examination of the human liver microsomal metabolism of the non-tricyclic anti-depressant nefazodone using data-dependent accurate mass measurements. J Am Soc Mass Spectrom 17:363–375
Li AC, Shou WZ, Mai TT, Jiang XY (2007) Complete profiling and characterization of in vitro nefazodone metabolites using two different tandem mass spectrometric platforms. Rapid Commun Mass Spectrom 21:4001–4008
Li AC, Shou WZ, Jiang XY (2009) Proposal of buspirone collision-induced dissociation rearrangement by exact mass measurements. Rapid Commun Mass Spectrom 23:1742–1745
Li AC, Ding J, Jiang X, Denissen J (2009) Two-injection workflow for a liquid chromatography/LTQ-Orbitrap system to complete in vivo biotransformation characterization: demonstration with buspirone metabolite identification. Rapid Commun Mass Spectrom 23:3003–3012
Lim H-K, Chen J, Sensenhauser C, Cook K, Subrahmanyam V (2007) Metabolite identification by data-dependent accurate mass spectrometric analysis at resolving power of 60,000 in external calibration mode using an LTQ/Orbitrap. Rapid Commun Mass Spectrom 21:1821–1832
Lim H-K, Chen J, Cook K, Sensenhauser C, Silva J, Evans DC (2008) A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution accurate mass spectrometry. Rapid Commun Mass Spectrom 22:1295–1311
Ruan Q, Peterman S, Szewc MA, Ma L, Cui D, Humphreys WG, Zhu M (2008) An integrated method for metabolite detection and identification using a linear ion trap/Orbitrap mass spectrometer and multiple data processing techniques: application to indinavir metabolite detection. J Mass Spectrom 43:251–261
Zhu M, Ma L, Zhang H, Humphreys WG (2007) Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography-high-resolution mass spectrometry and mass defect filtering. Anal Chem 79:8333–8341
Zhu M, Ma L, Zhang D, Ray K, Zhao W, Humphreys WG, Skiles G, Sanders M, Zhanh H (2006) Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metab Dispos 34:1722–1733
Zhu M, Zhao W, Jimenez H, Zhanh D, Yeola S, Dai R, Vachharajani N, Mitroka J (2005) Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos 33:500–507
Zhang D, Cheng PT, Zhang H (2007) Mass defect filtering on high resolution LC/MS data as a methodology for detecting metabolites with unpredictable structures: identification of oxazole-ring opened metabolites of muraglitazar. Drug Metab Lett 1:287–292
Zhang H, Zhang D, Ray KL (2003) A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses. J Mass Spectrom 38:1110–1112
Zhang H, Zhu M, Rey KL, Ma L, Zhang D (2008) Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection. Rapid Commun Mass Spectrom 22:2082–2088
Cho R, Huang Y, Schwartz JC, Chen Y, Carlson TJ (2012) MSM, an efficient workflow for metabolite identification using hybrid linear ion trap orbitrap mass spectrometer. J Am Soc Mass Spectrom 23:880–888
Wrona M, Mauriala T, Bateman KP, Mortishire-Smith RJ, O’Conner D (2005) ‘All-in-one’ analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Commun Mass Spectrom 19:2597–2602
Bateman KP, Castro-Perez J, Wrona M, Shockcor JP, Yu K, Oballa R, Nicoll-Griffith DA (2007) MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun Mass Spectrom 21:1485–1496
Tiller PR, Yu S, Castro-Perez JM, Fillgrove KL, Baillie TA (2008) High-throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time-of-flight system as a ‘first-line’ approach for metabolite identification studies. Rapid Commun Mass Spectrom 22:1053–1061
Barbara JE, Castro-Perez JM (2011) High-resolution chromatography/time-of-flight MSE with in silico data mining is an information-rich approach to reactive metabolite screening. Rapid Commun Mass Spectrom 25:3029–3040
Plumb RS, Jones MD, Rainville P, Castro-Perez JM (2007) The rapid detection and identification of the impurities of simvastatin using high resolution sub 2 micron particle LC coupled to hybrid quadrupole time of flight MS operating with alternating high-low collision energy. J Sep Sci 30(16):2666–2675
Hernandez F, Bijlsma L, Sancho JV, Diaz R, Ibanez M (2011) Rapid wide-scope screening of drugs of abuse, prescription drugs with potential for abuse and their metabolites in influent and effluent urban wastewater by ultrahigh pressure liquid chromatography–quadrupole-time-of-flight-mass spectrometry. Anal Chim Acta 684:96–106
Bijlsma L, Sancho JV, Hernandez F, Niessen WMA (2011) Fragmentation pathways of drugs of abuse and their metabolites based on QTOF MS/MS and MS(E) accurate-mass spectra. J Mass Spectrom 46:865–875
Geromanos SJ, Vissers JPC, Silva JC, Dorschel CA, Li G-Z, Gorenstein MV, Bateman RH, Langridge JI (2009) The detection, correlation, and comparison of peptide precursor and product ions from data independent LC-MS with data dependant LC-MS/MS. Proteomics 9:1683–1695
Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. J Drug Metab Dispos 36:386–399
Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K (2010) The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. J Drug Metab Dispos 38:667–678
Kanu AB, Dwivedi P, Tam M, Matz L, Hill HH (2008) Ion mobility-mass spectrometry. J Mass Spectrom 43(1), and literature cited therein
Castro-Perez J, Roddy TP, Nibbering NMM, Shah V, McLaren DG, Previs S, Attygalle AB, Herath K, Chen Z, Wang SP, Mitnaul L, Hubbard BK, Vreeken RJ, Johns DG, Hankemeier T (2011) Localization of fatty acyl and double bond positions in phosphatidylcholines using a dual stage CID fragmentation coupled with ion mobility mass spectrometry. J Am Mass Spectrom 22:1552–1567
Cuyckens F, Wassvik C, Mortishire-Smith RJ, Tresadern G, Campuzano I, Claereboudt J (2011) Product ion mobility as a promising tool for assignment of positional isomers of drug metabolites. Rapid Commun Mass Spectrom 25:3497–3503
Hamilton RA, Garnett WR, Kline BJ (1981) Determination of mean serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:250–251
Hop CE, Wang Z, Chen Q, Kwei G (1998) Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–903
Giles K, Williams JP, Campuzano I (2011) Enhancements in travelling wave ion mobility resolution. Rapid Commun Mass Spectrom 25:1559–1566
Pringle SD, Giles K, Wildgoose JL, Williams JP, Slade SE, Thalassinos K, Bateman RH, Bowers MT, Scrivens JH (2007) An investigation of the mobility separation of some peptide and protein ions using a new hybrid quadrupole/travelling wave IMS/oa-TOF instrument. Int J Mass Spectrom 261:1–12
Crecelius AC, Baumgaertel A, Schubert US (2009) Tandem mass spectrometry of synthetic polymers. J Mass Spectrom 44:1277–1286